Will Phase 2 UBT251 trial progress lift Novo Nordisk stock? Key levels to watch

Traders Union
All News
Financial News
Novo Nordisk slides 0.41% to $49.08

Highlights

Novo Nordisk advanced its Phase 2 trial of once-weekly UBT251 for Type 2 diabetes, reinforcing pipeline development momentum.
The trial progress highlights sustained R&D focus, but has not notably affected share price amid muted trading.
Technicals show prevailing bearish momentum, with a projected $48.46 to $49.70 range and sideways-to-downward bias in coming days.

Pipeline progress tempers sentiment amid muted trading response

Novo Nordisk has provided an update on its ongoing Phase 2 clinical trial assessing once-weekly subcutaneous UBT251 for Type 2 diabetes patients, according to Tipranks. This disclosure signals continued progress in the company’s product pipeline, potentially supporting prospects for future portfolio expansion. While the study’s advancement maintains market attention on Novo Nordisk’s R&D efforts, its immediate price impact appears limited amidst subdued trading activity.

Uneven momentum persists as key averages and oscillators diverge

On the technical front, NVO trades below both the MA-20 and MA-50 on the hourly chart, while remaining above the MA-200 level. The Ichimoku Kijun line at $48.98 defines immediate support for the stock. Oscillator readings are mixed: the Moving Average Convergence Divergence (MACD) signals a sell, Average Directional Index (ADX) is neutral, Relative Strength Index (RSI) stands at 47.71 with a sell signal, and Commodity Channel Index (CCI) is neutral. Stochastic RSI also points to selling conditions, while the Awesome Oscillator remains neutral and Bull/Bear Power suggests modest buyer dominance intraday, indicating uneven momentum.

Sideways trend expected as breakout risks hinge on short-term momentum

Looking ahead, NVO is expected to trade within a narrow corridor between $48.46 and $49.70 over the coming days. There is a 35% probability of an upward break above $49.70 resistance, while a 65% likelihood favors a move lower beneath the $48.46 support. The baseline scenario anticipates a sideways trend within this volatility band, with breakout moves dependent on shifts in short-term momentum.

Anton Kharitonov, expert at Traders Union, sees Novo Nordisk shares stuck between weak near-term momentum and a largely neutral response to their latest clinical update. Technical signals point to greater downside risk below $48.46, with sellers still active in the short and medium term. He believes immediate news flow lacks the strength to shift sentiment or break the current range. "Base case remains sideways unless $49.70 is reclaimed — otherwise, I stay cautious on new longs."

Earlier, analysts noted that Novo Nordisk shares were exhibiting ongoing buyer dominance and neutral momentum signals, with attention focused on support levels as potential inflection points. The current analysis introduces pipeline progress as an additional factor but highlights heightened downside risk, making the $48.46 support level crucial to monitor for any signs of further weakness.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.